Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 2063-2069

  Atfy, Maha ^a   Eissa, Mohamad ^a   Salah, Hossam E ^a   El Shabrawy, Deena A ^b  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Benha University   (Egypt)

Author keywords

Acute myeloid leukemia; CD87; Prognosis; Urokinase plasminogen activator receptor

Indexed keywords

CD34 ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; UROKINASE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; FLOW CYTOMETRY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84872799134     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9993-x     Document Type: Article

References (25)

1. Béné MC, et al. On behalf of EGIL, European Group on Immunological Classification of Leukemias. CD87 (urokinasetype plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 2004;18:394-400.
2. Lijnen HR. Pathophysiology of the plasminogen-plasmin system. Int J Clin Lab Res. 1996;26:1-6.
3. Stephans S, Yamamoto B. Methamphetamines pretreatment and the vulnerability of the stratum to methamphetamine neurotoxicity. Neuroscience. 1996;72(3):593-600.
4. Bu G, Warshawsky I, Schwartz AL. Cellular receptors for the plasminogen activators. Blood. 1994;83:3427-36.
5. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15: 398-408.
6. Lanza F, et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukemic cells. Br J Haematol. 1998;103:110-23.
7. Almeida J, et al. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulation of normal human peripheral blood MHC + lineage cells. Clin Exp Immunol. 1999;188:392-409.
8. Plesner T, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hemopoietic tissue. Am J Clin Pathol. 1994;102:835-41.
9. Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
10. Giles FJ, et al. Acute myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2002;2002(1):73-110.
11. Lowenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:65-75.
12. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML RAEB-t, and RAEB. Blood. 2000;95:72-7.
13. Knapp W, Strobl H, Majdic O. Flow cytometric analysis of cellsurface and intracellular antigens in leukemia diagnosis. Cytometry. 1994;18:187-98.
14. Graf M, Reif S, Hecht K, Pelka-Fleischer R, Pfister K, Schmetzer H. High Expression of Urokinase Plasminogen Activator Receptor (UPA-R) in Acute Myeloid Leukemia (AML) Is Associated With Worse Prognosis. Am J Hematol. 2005;79: 26-35.
15. Simon D, Rao N, Yu H, et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood. 1996;88:3185-94.
16. Castagnari B, et al. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells. Boll Soc Ital Biol Sper. 1995;71(5-6):141-7.
17. Reuning U, Magdolen V, Hapke S, Schmitt M. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem. 2003;384(8):1119-31.
18. Schmetzer HM, Wilmanns W, Gerhartz HH. Detection of acute myeloid leukemic cells in complete remission and in extramedullary sites by clonal analyses. Acta Haematol. 1996;96(2):83-7.
19. Champelovier P, et al. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol Res. 2002;30(5):301. Epub 2002 Aug 15.
20. Guthaus E, et al. The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPAreceptor interaction. Recent Results Cancer Res. 2003;162:3-14.
21. Ferrara F, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2000;18:1295-300.
22. Raspadori D, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15:1161-4.
23. Mason DK, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev. 2006;20:71-82.
24. Plesa C, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. A single-institution experience. Cancer. 2008;112(3):572-80.
25. Repp R, et al. Immunophenotyping Is an Independent Factor for risk Stratification in AML. Cytometry Part B (Clinical Cytometry). 2003;53B:11-9.